Publications by authors named "Anna Butusova"
The EMCV L and 2A proteins are virulence factors that counteract host cell defense mechanisms. Both L and 2A exhibit antiapoptotic properties, but the available data were obtained in different cell lines and under incomparable conditions. This study is aimed at checking the role of these proteins in the choice of cell death type in three different cell lines using three mutants of EMCV lacking functional L, 2A, and both proteins together.
View Article and Find Full Text PDFBackground & Aims: The complex tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) has hindered the development of reliable predictive biomarkers for targeted therapy and immunomodulatory strategies. A comprehensive characterization of the TME is necessary to advance precision therapeutics in PDAC.
Methods: A transcriptomic profiling platform for TME classification based on functional gene signatures was applied to 14 publicly available PDAC datasets (n = 1657) and validated in a clinically annotated independent cohort of patients with PDAC (n = 79).
Article Synopsis
- Relapse after lung adenocarcinoma (LUAD) surgery is common, and this study explores how features of the tumor microenvironment (TME), specifically B-cell infiltration, impact patient survival.
- The analysis involved over 1500 LUAD specimens, using whole exome and RNA sequencing to correlate B-cell presence with relapse-free survival and overall survival (OS).
- Results indicate that a higher B-cell content is linked to better OS, especially with naive B-cells, suggesting that B-cell abundance could be an important predictor for patient outcomes following surgery.
Article Synopsis
- Tissue-agnostic therapies have broadened treatment options for advanced solid tumor patients, with FDA approvals for pembrolizumab and TRK inhibitors like larotrectinib and entrectinib emphasizing the need for next-generation sequencing (NGS).
- A case study of a 64-year-old woman with triple-negative breast cancer, resistant to multiple treatments, revealed a rare mutation through NGS that enabled effective targeted therapy.
- After being treated with the TRK inhibitor larotrectinib, the patient experienced significant improvements in her condition, highlighting the importance of personalized medicine and NGS in cancer treatment.